BR112017007673A2 - modelagem corporal - Google Patents

modelagem corporal

Info

Publication number
BR112017007673A2
BR112017007673A2 BR112017007673A BR112017007673A BR112017007673A2 BR 112017007673 A2 BR112017007673 A2 BR 112017007673A2 BR 112017007673 A BR112017007673 A BR 112017007673A BR 112017007673 A BR112017007673 A BR 112017007673A BR 112017007673 A2 BR112017007673 A2 BR 112017007673A2
Authority
BR
Brazil
Prior art keywords
prodrugs
prodrug
adipose tissue
invention further
further relates
Prior art date
Application number
BR112017007673A
Other languages
English (en)
Inventor
Flik Gunnar
Willem Frijlink Henderik
Johan Woerdenbag Herman
Cremers Thomas
Original Assignee
Sculpt B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sculpt B V filed Critical Sculpt B V
Publication of BR112017007673A2 publication Critical patent/BR112017007673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C219/30—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção se refere a uma composição farmacêutica para administração tópica, compreendendo um pró-fármaco para um agonista e/ou um antagonista para um receptor adrenérgico, em que o pró-fármaco possui um coeficiente de partição octanol/água de pelo menos 0, para utilização em um método de modelagem corporal de um mamífero através da modulação do tecido adiposo subcutâneo. a invenção adicionalmente se refere à aplicação cosmética e terapêutica de tais pró-fármacos, tais como a sua utilização em métodos de modelagem corporal de um mamífero através da modulação local do tecido adiposo subcutâneo. a invenção adicionalmente se refere aos pró-fármacos propriamente ditos, bem como aos métodos de produção destes pró-fármacos.
BR112017007673A 2014-10-14 2015-10-14 modelagem corporal BR112017007673A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013634 2014-10-14
PCT/NL2015/050722 WO2016060564A1 (en) 2014-10-14 2015-10-14 Body sculpting

Publications (1)

Publication Number Publication Date
BR112017007673A2 true BR112017007673A2 (pt) 2017-12-19

Family

ID=52014321

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007673A BR112017007673A2 (pt) 2014-10-14 2015-10-14 modelagem corporal

Country Status (11)

Country Link
US (2) US20170231885A1 (pt)
EP (1) EP3206678B1 (pt)
JP (1) JP2017534610A (pt)
CN (1) CN106999465B (pt)
BR (1) BR112017007673A2 (pt)
CA (1) CA3001981A1 (pt)
DK (1) DK3206678T3 (pt)
EA (1) EA201790693A1 (pt)
ES (1) ES2777549T3 (pt)
PT (1) PT3206678T (pt)
WO (1) WO2016060564A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9941388B2 (en) * 2014-06-19 2018-04-10 Globalfoundries Inc. Method and structure for protecting gates during epitaxial growth
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2018218012A1 (en) 2017-05-24 2018-11-29 Follea International Synephrine compositions
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
EP3720858B1 (en) 2017-12-06 2023-06-07 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
CN108379209B (zh) * 2018-05-09 2020-12-04 佛山市百分之秀化妆品有限公司 一种孕妇用护肤品及其制备方法
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
US20220062213A1 (en) * 2020-09-02 2022-03-03 Jubilant Pharma Holdings Inc. Methods and compositions of solabegron for reducing body fat
WO2023187116A1 (en) 2022-03-30 2023-10-05 Rheinische Friedrich-Wilhelms-Universität Bonn Mirabegron formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI55988C (fi) * 1971-10-19 1979-11-12 Klinge Co Chem Pharm Fab Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer
DE2341876A1 (de) * 1973-08-18 1975-03-13 Boehringer Sohn Ingelheim Neue 1-(m-acyloxyphenyl)-1-hydroxy- 2-n-alkylamino-aethane, deren saeureadditionssalze, diese enthaltende arzneimittel, sowie verfahren zu ihrer herstellung
CA1193198A (en) * 1982-11-11 1985-09-10 Bernard Loev Antiglaucoma compounds
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US20040235922A1 (en) * 2003-05-15 2004-11-25 Baile Clifton A. Compositions and methods for inducing adipose tissue cell death
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
ATE552032T1 (de) * 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB0526123D0 (en) * 2005-12-22 2006-02-01 Univ Gent Synephrine derivatives useful as anti-inflammatory agents
AU2007231488A1 (en) * 2006-03-24 2007-10-04 National Research Council Of Canada Anti-diabetic cataract compounds and their uses
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN103113244B (zh) * 2013-02-26 2015-06-03 湖南鑫利生物科技有限公司 一种可透皮吸收辛弗林衍生物的制备方法

Also Published As

Publication number Publication date
ES2777549T3 (es) 2020-08-05
US20170231885A1 (en) 2017-08-17
CA3001981A1 (en) 2016-04-21
CN106999465A (zh) 2017-08-01
EP3206678B1 (en) 2019-12-11
EA201790693A1 (ru) 2017-09-29
DK3206678T3 (da) 2020-03-16
JP2017534610A (ja) 2017-11-24
WO2016060564A1 (en) 2016-04-21
CN106999465B (zh) 2020-08-14
WO2016060564A8 (en) 2017-06-15
US20210220241A1 (en) 2021-07-22
PT3206678T (pt) 2020-03-23
EP3206678A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
BR112017007673A2 (pt) modelagem corporal
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112018070361A2 (pt) redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
BR112017012927A2 (pt) partícula compósita, processo cosmético e métodos para a preparação de uma partícula compósita
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
BR112016006951A2 (pt) novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112018068293A2 (pt) malassezina e seus análogos como agentes de clareamento de pele
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.